Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluering av effektene av prebiotiske og fiberintervensjoner på søvn, tarmmikrobiomet, kognisjon og stress.

9. november 2026 oppdatert av: Northumbria University

Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress

This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.

Interested participants will initially be scheduled to complete a screening telephone call with the researcher. Here, electronic informed consent will first be provided by the participant, by accessing a pre-emailed link to the Qualtrics survey platform, to an account which is hosted by Northumbria University. Once consent is obtained, the participant will confirm that they do not meet any of the study exclusion criteria, and will complete the SDS-CL checklist with the researcher, over the phone. If any clinical thresholds are met, participants will be invited to a separate clinical interview (again via phonecall) with Professor Jason Ellis, employing the International Classification of Sleep Disorders (ICSD-3) criteria, to determine elligibility.

If participants progress to enrolment, they will be invited to attend a lab-based training/screening session (protocol day -7) at Northumbria University. Here, hard and wet-signed (by both the participant and the researcher) consent forms will be completed and stored on site. Participants will then be familiarised with the study protocol and procedures. Participants will also be trained on the cognitive tasks. During the following 7 nights (Protocol days -7 to -1), participants will monitor their sleep and complete the daily Sleep Diary each morning. During this week, they will also drop off their pre-dose baseline stool sample at a remote drop-off location at Northumbria University.

Seven days following the lab-based screening visit (Supplement day 1, Protocol day 0), participants will attend the laboratory for their acute visit. Here, a pre-dose baseline sample of saliva and a single blood sample will be taken (for Alpha Amylase, Cortisol, Serotonin and Melatonin), and Blood Pressure, Heart Rate, Body Mass Index, and Waist-to-Hip Ratio will be measured. Participants will complete the Intake24 dietary assessment, and gastrointestinal symptoms questionnaires, as well as the Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), and Depression, Anxiety and Stress Scale - 21 Items (DASS-21). The cognitive task battery will additionally be completed.

After completing these measures, participants will receive instructions on the next phase of the trial. From that night, participants will consume their first dose of the investigational supplement (noting the time in their treatyment diary) 4 hours before their normal bed-time. They will monitor their sleep overnight. The following morning (supplementation day 2, protocol day 1), participants will complete their Sleep Diary. Participants will follow this procedure for the following 27 days. At some point during Protocol (Days 12-18), participants will return to Northumbria University to drop-off their interim stool sample.

On Protocol day 28, participants will return to the lab for the chronic testing visit. All of the outcome measures assessed during the acute lab visit (Protocol day 0) will be repeated here. At the end of the session, participants will be debriefed, and their participation payment arranged. At some point during Protocol (Days 27-33) participants will return to Northumbria University to drop-off their chronic stool sample.

Studietype

Intervensjonell

Registrering (Faktiske)

69

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Newcastle upon Tyne, Storbritannia
        • Northumbria University- Northumbria Sleep center and NUTRAN

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

25 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

INCLUSION CRITERIA

  • Participants must self-assess themselves as being in good health.
  • Aged 25 to 60 years at the time of randomisation
  • Fluent in English
  • Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of >5 on the Pittsburgh Sleep Quality Index (PSQI).

EXCLUSION CRITERIA

  • Member of own household currently participating in this trial
  • Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and/or sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder
  • History of seizures or epilepsy
  • Shift working or have a history of shift work within the previous six months
  • Currently, or within the previous 8 weeks, consuming any nutritional supplements.
  • Participation in any other intervention research trials
  • Sleeping at a location other than their usual residence more than two nights per week during participation
  • Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study
  • Current or recent mood disturbances or Axis I disorders (descriptions will be given)
  • Current misuse of alcohol and/or drugs
  • Current smoker
  • Recent (within the last 12 weeks) infection and/or use of antibiotic medication
  • Pregnant, seeking to become pregnant or lactating
  • Those using (including within the last 2 weeks) proton-pump inhibitors

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm 1

Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days.

A proprietary orally administered dietary supplement consisting of standardized ingredients.

Eksperimentell: Arm 2

Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days.

A proprietary orally administered dietary supplement consisting of standardized ingredients.

Placebo komparator: Control

Participants will be randomly allocated to consume control supplement for 28 days.

Flavored vehicle

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sleep Efficiency (SE)
Tidsramme: Change from Baseline to end of supplementation period at 28 days

Sleep efficiency (SE), commonly defined as the ratio of total sleep time (TST) to time in bed (TIB), will be reported as a percentage of time in bed.

Change from Baseline to end of supplementation period at 28 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Actigraphy - Sleep onset latency
Tidsramme: Change from baseline following 28 days of supplement consumption

recorded minutes taken from intention to sleep to sleep initiation

Change from baseline following 28 days of supplement consumption
Actigraphy - Sleep efficiency
Tidsramme: Change from baseline following 28 days of supplement consumption

ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage)

Change from baseline following 28 days of supplement consumption
Actigraphy - Number of awakenings
Tidsramme: Change from baseline following 28 days of supplement consumption

recorded number of awakenings during entire sleep period

Change from baseline following 28 days of supplement consumption
Actigraphy - Wake after sleep onset (WASO)
Tidsramme: Change from baseline following 28 days of supplement consumption

recorded minutes awake during the entire sleep period following sleep onset

Change from baseline following 28 days of supplement consumption
COMPASS global performance measures
Tidsramme: Change from baseline following 28 days of supplement consumption

Speed of performance, and accuracy of performance measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)

Change from baseline following 28 days of supplement consumption
Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: Change from baseline following 28 days of supplement consumption

Pittsburgh Sleep Quality Index (PSQI): Total Score. The PSQI is a validated self-rating instrument assessing aspects of sleep quality.Minimum score 0 (better); maximum score 21 (worse) < or = 5 associated with good sleep quality; > 5 associated with poor sleep quality.

Change from baseline following 28 days of supplement consumption
Depression, Anxiety and Stress Scale - 21 Items (DASS-21)
Tidsramme: Change from baseline following 28 days of supplement consumption

A 21-item measure of mood over the previous week (each item is rated on scale from 0-3). Scoring creates 3 component scores: depression, anxiety and stress (each on a scale of 0-21) with higher scores indicating higher symptomology. Cut-off scores, according to each set of symptoms, are available (normal, mild, moderate, severe and extremely severe) or total scores can be derived by multiplying the sum of all three component scores by 2.

Change from baseline following 28 days of supplement consumption
State-Trait Anxiety Inventory (STAI)
Tidsramme: Change from baseline following 28 days of supplement consumption

A 40-item measure of current and general anxiety levels. Each item is rated on a scale from 1-4. Scoring creates two components: state anxiety (20 items) and trait anxiety (20 items), with a range for each between 20-80. Following transformation through reversed coding, higher scores indicate higher levels of anxiety

Change from baseline following 28 days of supplement consumption
Actigraphy - Total sleep time
Tidsramme: Change from baseline following 28 days of supplement consumption

recorded minutes asleep over entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Total sleep time
Tidsramme: Change from baseline following 28 days of supplement consumption

recorded minutes asleep over entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Sleep onset latency
Tidsramme: Change from baseline following 28 days of supplement consumption

logged minutes taken from intention to sleep to sleep initiation

Change from baseline following 28 days of supplement consumption
Sleep Diary - Sleep efficiency
Tidsramme: Change from baseline following 28 days of supplement consumption

ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage)

Change from baseline following 28 days of supplement consumption
Sleep Diary - Number of awakenings
Tidsramme: Change from baseline following 28 days of supplement consumption

logged number of awakenings during entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Wake after sleep onset (WASO)
Tidsramme: Change from baseline following 28 days of supplement consumption

logged minutes awake during the entire sleep period following sleep onset

Change from baseline following 28 days of supplement consumption

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Professor Jason Ellis, PhD, Northumbria University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. april 2026

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. april 2027

Datoer for studieregistrering

Først innsendt

19. januar 2026

Først innsendt som oppfylte QC-kriteriene

19. januar 2026

Først lagt ut (Faktiske)

27. januar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. februar 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 000000

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .